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Abstract 
The indicators’ values of health condition of the Slovak citizens significantly lag behind the most developed countries. The 
issue of healthy inhabitants is more connected with a treatment of bad health condition than with a non-health prevention, 
which is believed to be caused by social and political development over the last decades. Measuring the influence of health 
system on inhabitants’ health is very difficult due to the influences of various factors, such as wealth, socio-economic 
status, citizen’s lifestyle, quality of environments, etc. Consequently, an amenable mortality indicator is used to evaluate the 
health system except of the life expectancy indicator. It defines a mortality that should not have occurred in case of 
effective and early treatment. It only takes into consideration those diagnoses, where effective treatment exists before a 
certain age limit (75 years) according to experts. The number of these deaths is standardized on 100,000 citizens. The 
amenable mortality indicator has a great significance for standard comparisons, however, its application also causes 
methodological issues, such as data quality of mortality, choice of diagnoses, weight of diagnoses, etc. In the international 
comparing, it is very often deduced from a fact that each country spends different amount of funds on health, while the 
differences may be connected with a different effectiveness of invested funds in the health systems. The article reflects on 
the given facts and its aim is to evaluate the development of amenable mortality in Slovakia over the last ten years, as well 
as to compare the development of this indicator in the EU countries. Similarly, it assesses the significant methodological 
issues that are related to indicator’s application and defines the causes of extreme differences that were found out by the 
results on the basis of the given outputs. 
 
© 2015 Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license  
(http://creativecommons.org/licenses/by-nc-nd/3.0/). 
Selection and peer-review under responsibility of the Emerging Markets Queries in Finance and Business local organization 
 
Keywords: amenable mortality; avoidable mortality; effectiveness; health systems financing  
 
 
*
 Corresponding author.  
E-mail address: beata.gavurova@tuke.sk
© 2015 The Authors. Published by Elsevier B.V. This is a  op n access article under the CC BY-NC-ND license 
(ht p:/ cre ti . r /licenses/by-nc-nd/4.0/).
Selection and peer-revie  un er r i ilit   Asociatia Grupul Roman de Cercetari in Fi ante Corporatiste
78   Beáta Gavurová and Tatiana Vagašová /  Procedia Economics and Finance  32 ( 2015 )  77 – 86 
1. Introduction  
There is general consensus that the main goal of health care systems is to improve health of population, so it 
is very important to assess the health systems’ performance, mainly their contribution to positive changes in the 
health of population. There are many ways how the effectiveness of the world health care systems could be 
measured (Antošová et al. 2014; Buzink et al., 2012; Šoltés et al., 2011). However, the health status does not 
only depend on health care systems operations. It is also influenced by non-medical factors, for instance 
lifestyle, socio-economic status, wealth and environmental factors (Užík, Šoltés, 2009; Glova, 2013a,b; 
Pavlíková, Siniþáková, 2012). These determinants can actually have a greater role in defining health status than 
health care (Závadská et al., 2013; Szabo et al., 2013; Vajda, Vravec, 2011; Vajda, 2009). However, the health 
systems all over the world are often compared to evaluate and improve the delivery of healthcare services to the 
patients (Dlouhý, Barták, 2013). The quality of health care and the assessment of its ability to improve the 
health of a patient represent an important determinant of the health care systems effectiveness in developed 
countries. As a first, Rutstein et al., 1976 defined “quality” as the effect of care as well on the individual health, 
as on population health. Improving the quality of health care should be reflected in better health outcomes. 
Hence, it is very beneficial to explore the share of better health status that can be attributed to effective and 
timely health care (Šoltés, RadoĖák, 2012a, 2012b; Šimrová et al. 2014). Consequently, researchers have 
developed the concept of amenable mortality – deaths avoidable through health care. Amenable mortality (AM) 
is generally defined as “premature deaths that should not occur in the presence of effective and timely care. It 
takes into account premature deaths of a list of diseases, for which effective health intervention exist and might 
prevent deaths before a certain age limit, usually 75” (Gay, J. G. et al., 2011). The main objectives of this paper 
are: 
• to evaluate the development of amenable mortality in Slovakia over the last decade;  
• to compare the development of this indicator in the EU countries; 
• to quantify the association between amenable mortality decline and health care funding levels. 
1.1. The concepts of avoidable and amenable mortality 
We are often faced with a confusion of two terms: avoidable mortality and amenable mortality. The 
difference lies in this way, that amenable mortality is a part of the avoidable mortality. Avoidable mortality was 
developed by a group of scientists from Harvard University (Rutstein et al., 1976). In their work, avoidable 
mortality was defined as “deaths from selected disease groups which are considered to be either treatable or 
preventable through health care services”. They introduced the notion of ”unnecessary untimely deaths” by 
suggesting a list of diseases from which death should not appear in the presence of timely and effective medical 
care. Medical care was determined in its broadest meaning as prevention, cure and care. 
The Harvard group was the first to introduce the notion “amenable mortality”, distinguishing between 
causes that are susceptible to treatment through medical procedures (e.g. neoplasms, diabetes mellitus and so 
on) and causes reacting to actions outside the health care (preventable conditions such as lung cancer or liver 
cirrhosis). In the collaboration with medical experts, Rutstein et al., 1976 made a list of around eighty 
avoidable causes of deaths. Examples gather diabetes, which should be treated by insulin; appendicitis, treated 
by surgery; lung cancer, which should be prevented by limited smoking, and so on. Amenable mortality was 
used by European researchers in the 1980s and 1990s (Mackenbach et al., 1990; Westerling, 1992; Holland et 
al., 1997). The concept has been renewed in recent years, due to the work of Nolte and McKee, 2008 and 
Tobias and Yeh, 2009. They restored the list based on the most recent advances in health knowledge and 
technology and allocated 34 causes of avoidable death. The recent study about amenable mortality is the EU-
funded project, ‘Avoidable Mortality in the European Union: towards better Indicators for the Effectiveness of 
Health Systems’ (abbreviated AMIEHS), led by Erasmus Medical University and coordinated jointly with the 
79 Beáta Gavurová and Tatiana Vagašová /  Procedia Economics and Finance  32 ( 2015 )  77 – 86 
London School of Hygiene and Tropical Medicine (AMIEHS, 2011). To conclude, development in mortality 
by preventable causes of deaths (preventable mortality) or amenable causes of deaths (amenable mortality), 
which are parts of total avoidable mortality, are also presented by Office for National Statistics in UK, 2013 
which offers the following definitions of amenable and preventable mortality: 
• Amenable mortality: „A death is amenable (treatable) if, in the light of medical knowledge and 
technology at the time of death, all or most deaths from that cause (subject to age limits if appropriate) could 
avoided through good quality health care.“ 
• Preventable mortality: „A death is preventable if, in the light of understanding of the determinants of 
health at time of death, all or most deaths from that cause (subject to age limits if appropriate) could be 
avoided by public health intervention in the broadest sense.“ 
It is necessary to take account that the concept of avoidable mortality is included in a group of premature 
deaths that should not be occurring in that time. Consequently, the occurrence or increasing of the avoidable 
mortality, admittedly, indicates the need to improve the quality of prevention or delivered health care services. 
We examined the level and trend of amenable mortality because it directly responses to quality of health care 
and thus, with effectiveness of health care system. 
2. Statistical data and methods 
2.1. Selection of causes of death  
According to the International Classification of Diseases (ICD-10th revision), we consider the list of causes 
of death by Nolte and McKee, 2008 (Appendix A.).We also included ischemic heart diseases (IHD), but we 
consider only 50% of the deaths from IHD as amenable according to the OECD methodology (Gay, J. G. et al., 
2011). Age limit, 75 years, was set for premature deaths, and reflects the average life expectancy at birth in 
developed countries (Gavurová, B., Šoltés, V., 2013). The problem appears above this age because the 
avoidability of deaths is less obvious and the identification of cause of death can become problematic (Newey 
et al., 2004). The age limit is applied on both gender categories – males and females. Lower age limits were 
applied to selected conditions (Appendix A.). These included diabetes mellitus (under age fifty) because the 
preventability of deaths at older ages from diabetes remains questionable; the childhood conditions of 
childhood intestinal infectious diseases, whooping cough, measles, and childhood respiratory diseases (under 
age fifteen); and leukaemia (under age forty-five). 
2.2. Data and methods  
AM rates were computed from data on deaths by cause, gender and five – year age groups from the World 
Health Organization (WHO) database which included data for 20 EU countries for years 2002 – 2012. 
Remaining eight EU countries were not included in the analysis because of the incompleteness of available 
data. As for Slovakia, National Health Information Center provided data of deaths for the recent year 2013. 
Data on mid-year population at the age groups and gender in every year were downloaded from the Statistical 
Database of the United Nations Economic Commission for Europe. Mortality rates for all conditions were age-
standardised according to the European Standard Population to allow international comparison in the future 
research. European Standard Population data by age groups were selected of the EUROSTAT web site. WHO 
also provided data about total expenditure on health per capita expressed in Purchasing Power Parities (PPP) 
international dollar. 
The rates of amenable mortality are expressed by the age–standardised death rates (ASDR)  
per 100,000 population. We applied the method of direct standardisation using the European Standard 
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Population. The purpose of the standardisation is to eliminate any effect from differences in the age structure 
across countries and over time. ASDR are computed by the following mathematic expression. 
¦
¦
=
x
x
x
xx
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Pm
ASDR
*
*
.
  (1) 
Where: 
x - age/sex group 0-4, 5-9,..., 70-74 
mx - observed mortality rate (deaths per 100,000 population) in sex/age group 
Px*- European Standard Population in sex/age group x 
 
Age-standardised death rates by sex were calculated for all causes of death considered amenable and for the 
age interface by direct standardisation to the European standard population. Analyses were undertaken using 
Microsoft Access and Excel for the period 2002-2012, 2002-2013 for Slovakia. 
2.3. Limitations  
There are several limitations of using this determinant to evaluate the performance improvement of health 
care systems. Originally, we considered to analyse all 28 EU countries, unfortunately, our analysis was limited 
to the small data availability of some countries. Other limitations are more related to the concept itself, for 
instance the selection of causes of death varies over time because of technological progress, or not consider 
whether required professional skills or technologies are available in a specific country for providing effective 
health intervention. AM does not consider available resources in each country. In our paper this limitation is 
partly eliminated by exploring the association between AM and health care funding levels in each country. 
3. Study Results 
3.1. Amenable mortality in Slovakia  
AM is an important contributor to overall mortality, according to Mészáros, 2008 amenable mortality in 
Slovakia accounted for approximately 50% of the total mortality rates. Trends of amenable mortality are 
decreasing, both in males and females. AM of males is about twice higher than rates of females by year-on-
year. It is related with the fact that life expectancy at birth for women has been higher compared to men over 
time (Gavurová, B., Šoltés, V., 2013). Between 2002 and 2013 rates of AM among men fell by 34.04% from 
295.17 to 194.71 per 100,000 population and by 32.44 % from 173.93 to 117.50 per 100,000 in females (Fig.1., 
Table 1.).Table 1 has showed that ASDR of causes of death which recorded the highest decline during the 
period 2002-2013, simultaneously, experienced the lowest contributions to overall AM. ASDR of respiratory 
diseases fell by 62.73% in males, while their contribution did not perform nor 0.1%. As for females, ASDR of 
misadventures to patients during surgical and medical care, which are directly connected with the effective 
health care, fell by 100% and their share on AM completely disappeared in 2013. Ischemic heart disease and 
other circulatory disease, such as cerebrovascular and hypertensive heart diseases, were the leading causes of 
AM in males in 2002, as well as in 2013. Other circulatory disease performed the decline of their contribution 
to overall AM comparing 2002 and 2013. Contribution of IHD slightly increased from 40.82% to 42.97%. 
Notable increase occurred in tumors which raised from 8.85% to 12.64%, while their annual change performed 
the lowest change of all (-5.77%).  
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Fig. 1. Trends in the ASDR for causes of death considered amenable per 100,000 population in Slovakia, by sex, ages 0-74, 2002 – 2013 
SOURCE: own processing 
Table 1. ASDR (per 100,000 population) from causes of death considered amenable and their contribution to total AM, 2002 and 2013, 
men, women 
MALE ASDR Annual change in % Contribution to overall AM 
Amenable causes  of death 2002 2013 2002 2013 
Infectious disease 12.62 11.14 -11.74% 4.28% 5.72%
Tumors 26.12 24.61 -5.77% 8.85% 12.64%
Diabetes (type 2) 1.01 0.70 -31.25% 0.34% 0.36%
Ischemic heart disease (50% of deaths) 120.50 83.67 -30.57% 40.82% 42.97%
Other circulatory disease 107.31 59.79 -44.28% 36.36% 30.71%
Respiratory diseases (excl. pneumonia, influenza) 0.20 0.07 -62.73% 0.07% 0.04%
Surgical conditions 20.40 9.77 -52.12% 6.91% 5.02%
Maternal, congenital and perinatal conditions 2.21 1.85 -16.17% 0.75% 0.95%
Other conditions 4.79 3.10 -35.30% 1.62% 1.59%
All amenable causes 295.17 194.71 -34.04% 100.00% 100.00%
FEMALE
Diabetes (type 2) 0.64 0.45 -30.13% 0.37% 0.38%
Infectious disease 4.96 5.71 15.12% 2.85% 4.86%
Ischemic heart disease (50% of deaths) 50.23 32.33 -35.64% 28.88% 27.51%
Maternal, congenital and perinatal conditions 2.63 2.10 -20.17% 1.51% 1.79%
Misadventures to patients during surgical and medical 
care 0.15 0.00 -100.00% 0.09% 0.00%
Other circulatory disease 57.00 27.57 -51.63% 32.77% 23.46%
Other conditions 1.07 0.89 -17.22% 0.62% 0.75%
Surgical conditions 11.04 3.99 -63.85% 6.35% 3.40%
Tumor 46.19 44.46 -3.74% 26.56% 37.84%
All amenable causes 173.93 117.50 -32.44% 100.00% 100.00%
SOURCE: own processing 
 
As for females, the key finding is increase of ASDR of infectious diseases from 4.96 per 100,000 in 2002 to 
5.71 in 2013, ie. by 5.72%. Slightly disturbing fact is that the proportion of tumors in overall AM increased 
from 26.56% in 2002 to 37.84% in 2013. This may indicate the alarming and negative results of oncological 
health care. Conversely, contribution of other circulatory diseases in females decreased significantly.  
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3.2. Development of amenable mortality in EU countries  
AM has decreased in all experienced EU countries over the 2002-2012 (Fig. 2). The average annual decline 
is 24.8%. Annual changes from 2002 to 2012 ranged from -6.6% in Lithuania to 
-39.7% in Estonia. Both countries belong to the Baltic States, however there are significant differences in their 
efforts to progressing of health outcomes, such as indicator of amenable mortality. Comparing countries of V4 
region, Slovakia achieved the highest decrease of AM (-28.9%), above the EU average (-24.8%). By contrast, 
decline of AM in Czech Republic (-24%), Hungary (-22.5%), Poland (-20%) was already comparatively lower 
and below the EU average.  
 
 
 
 
 
 
 
 
 
 
Fig. 2. Annual change in AM, 2002 to 2012 (or latest available year); Note: (1) 2011 for Denmark, Finland, Netherlands, Luxembourg, 
Malta, Poland, Romania, Spain; (2) 2010 data for France, Lithuania, Slovenia, Sweden, United Kingdom  
SOURCE: own processing 
Appendix B. shows an analysis of AM in 2012 or latest available year, by gender, in experienced EU 
countries. The aim of this analysis was to explore the current level of AM in experienced countries. In all 
countries AM was higher in males than in females. As for males, EU average of AM performs 158 deaths per 
100,000 population. Countries with the lowest values are Netherland (58 per 100,000), France (59 per 
100,000), Luxembourg (66 per 100,000). Netherland also recorded significantly decrease of AM (-31.8%) 
during the last decade (Fig.2). Currently, in males the worst values of AM have just the Baltic States: Latvia 
(327 per 100,000), Lithuania (315 per 100,000), Estonia (257 per 100,000) and could be achieved more 
progress. Slovakia´s ASDR (210 per 100,000) is worse than the EU average (158 per 100,000). As for females, 
countries with the lowest values of AM are Spain (53 per 100,000), France (53 per 100,000), Luxembourg (58 
per 100,000). In Latvia (164 per 100,000), Lithuania (162 per 100,000) and Romania (161 per 100,000), by 
contrast, AM is already comparatively high. 
83 Beáta Gavurová and Tatiana Vagašová /  Procedia Economics and Finance  32 ( 2015 )  77 – 86 
3.3. Regression between mortality decline and health care funding levels in EU countries 
The third aim of this paper is to explore the regression between the ASDR per 100,000 population in EU 
countries and per capita total expenditure on health expressed in PPP int.$ in 2012. Data source is available in 
Appendix C. In this analysis power type regression has been demonstrated. Determination index (R²) indicates 
that 81.55% of dependency of our data is explained by power type regression. With the increase per capita total 
expenditure on health by 1 unit, the lower decrease of ASDR per 100,000 can be expected as 1 unit. The least 
sum of money on health is given by Romania (872.9), and also the ASDR per 100,000 belong to the highest of 
EU countries (195.23). On the contrary, Luxembourg (6340.6) contributes the highest amount on health, and its 
AM performs one of the lowest levels of ASDR per 100,000 (61.54).  
 
 
 
 
 
 
 
 
Fig. 3. Health care expenditures and AM in EU countries, 2012 or latest available year 
SOURCE: own processing  
Among the countries lying, approximately, on the same horizontal line, the countries staying more on the 
left side are more effective because they have comparable AM ensured by the less amount of money. On the 
other hand, comparing Slovakia (SVK) and Czech Republic (CZE), both countries give almost the same sum of 
money on health; however ASDR in Slovakia (160.81) is higher than in Czech Republic (116.78). 
4. Conclusion 
Scientists have developed the concept of AM as a possible indicator for measuring the effectiveness of 
health care systems by preventing premature deaths that can be avoided by appropriate health care intervention. 
However, this concept of AM should be regarded together with the available resources connected with health 
care systems. Our paper offers the following key findings. First of all, we found that the trend of development 
of AM has been decreasing in Slovakia over the 2002-2013 period. In both sexes, the shares of tumors on 
overall AM have increased rapidly and we have recorded in females increase of infectious diseases over the 
2002-2013. Secondly, comparing the level of AM in 2012 and development of AM over 2002-2012 in EU 
countries, we found that some countries, such as Estonia in spite of its high level of ASDR in 2012, had the 
highest decrease of ASDR over the last decade. Compared to Lithuania and Latvia which also performed the 
highest values of AM in 2012, conversely they did not show any effort to improve their negative situation 
because their decreases of ASDR over the last decade belong to the worst. As for countries of region V4, 
Slovakia has performed the highest decline of AM over the 2002-2012, but its current level of ASDR per 
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100,000 is the second worst of V4 countries. Thirdly, we quantify the power type regression between the 
ASDR per 100,000 population in EU countries and per capita total expenditure on health expressed in PPP int.$ 
in 2012. These countries, which lie below the trend line, can be marked with more effective health care system 
with compare to the countries above the trend line. It is challenge to find the optimal point between funding 
levels and amenable mortality. Rates of AM likely reflect the influence of many different factors, which in at 
least some cases also include health care effectiveness. This implies that they must be interpreted with caution, 
and do not without further analysis permit judgements on the effectiveness of health care systems. The main 
conclusion is that the concept of AM and its appealing concept provide new message that is not directly 
included in general mortality indicators mostly used to measure the health outcomes in the world health care 
systems. While improving health is the main objective of health systems, measurement the contribution of 
health care systems to the population health remains a challenge.  
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Appendix A. List of causes of death considered amenable to health care 
Cause of death considered amenable to health care Age ICD - 10th revision 
Infectious disease   
    Tuberculosis 0-74 A15-A19, B90 
    Selected invasive infections 0-14 A00-09, A37, B05  
 0-74 A35-36, A40-41, A80, J10-18 
Tumor   
   Colorectal cancer 0-74 C18-21 
   Malignant neoplasms of skin 0-74 C44 
   Breast cancer 0-74 C50 
   Cervical cancer 0-74 C53 
   Uterine cancer 0-44 C54-55 
   Testis cancer 0-74 C62 
   Hodgkin’s disease 0-74 C81 
   Leukaemia 0-44 C91-95 
Diabetes (type 2) 0-49 E10-14 
Ischemic heart disease (50% of deaths) 0-74 I20-25 
Other circulatory disease   
  Rheumatic & other valvular heart disease 0-74 I05-09 
  Hypertensive heart disease 0-74 I10-13, I15 
  Cerebrovascular disease 0-74 I60-69 
Respiratory diseases (excl. pneumonia, influenza) 0-14 J00-09, J20-99 
Surgical conditions   
   Peptic ulcer disease 0-74 K25-27 
   Acute abdomen, appendicitis, intestinal obstruction, 0-74 K35-38, K40-46, K80-81 
   cholecystitis/lithiasis, pancreatitis, hernia   
   Nephritis & nephrosis 0-74 N00-07, N17-19, N25-27 
   Obstructive uropathy & prostatic hyperplasia 0-74 N40 
Misadventures to patients during surgical & medical care 0-74 Y60-69, Y83-84 
Maternal, congenital and perinatal conditions   
   Maternal deaths 0-74 O00-99 
   Perinatal deaths, all causes (excl. stillbirths) 0-74 P00-96 
   Congenital malformations 0-74 Q20-28 
Other conditions   
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   Thyroid disorders 0-74 E00-07 
   Epilepsy 0-74 G40-41 
SOURCE: Adapted from Nolte & McKee 2008   
Appendix B. Amenable mortality by gender, 2012 or latest available year  
 
SOURCE: own processing 
Appendix C. Health care expenditures per capita and amenable mortality in EU countries, 2012 or latest 
available year 
Country Abbreviation 
Per capita total expenditure on health 
 (PPP int. $). 2012 
Amenable mortality rates 
(death per 100 000 population). 2012 
Czech Republic CZE 2046 116.78
Denmark DNK 4719.8 71.76
Estonia EST 1385.4 177.32
Finland FIN 3544.7 82.89
France FRA 4260.2 56.16
Netherlands NLD 5384.6 61.47
Croatia HRV 1409.8 123.23
Lithuania LTU 1426.3 225.18
Latvia LVA 1188.1 228.91
Luxembourg LUX 6340.6 61.54
Hungary HUN 1729.3 188.95
Malta MLT 2547.7 89.52
Germany DEU 4617 74.28
Poland POL 1489.3 122.67
Romania ROM 872.9 195.23
Slovakia SVK 1976.8 160.81
Slovenia SVN 2419.9 86.06
Spain ESP 3144.9 60.96
Sweden SWE 4157.8 67.25
United Kingdom GBR 3494.9 74.74
SOURCE: own processing 
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